Journal of the American Academy of Child & Adolescent Psychiatry
New ResearchThe MTA at 8 Years: Prospective Follow-up of Children Treated for Combined-Type ADHD in a Multisite Study
Section snippets
Participants
The MTA participants were 579 children with DSM-IV ADHD combined type. Each of the six participating sites randomized 96 to 98 children to one of four treatment groups (MedMgt, Beh, Comb, and CC). At baseline (pretreatment), participants were 7.0 to 9.9 years of age (mean 8.5 years, SD 0.8 years). The MTA recruitment strategy, procedures for diagnosing ADHD, treatment specifics, and sample demographics have been described elsewhere.1, 2, 4, 5, 10, 11, 12, 13, 14
Participants were reassessed at
Medication Use Over Time
We first examined medication use because of its importance as a covariate in determining long-term treatment effects. As previously reported,6 medication use varied at 14, 24, and 36 months according to initial random assignment: mean (SD)—0.71 (0.24), 0.67 (0.35), 0.66 (0.41) for MedMgt; mean (SD)—0.71 (0.22), 0.69 (0.35), 0.67 (0.39) for Comb; mean (SD)—0.16 (0.28), 0.35 (0.44), 0.43 (0.46) for Beh; mean (SD)—0.54 (0.41), 0.58 (0.42), 0.59 (0.43) for CC, respectively. By the 6- and 8-year
Discussion
Three sets of findings resulted from this prospective longitudinal study of the MTA children into adolescence. Intent-to-treat analyses revealed no appreciable differences among the children based on their randomized treatment group assignment at 7 to 9 years of age. The ADHD symptom trajectory in childhood, however, was a strong predictor of outcome at both 6 and 8 years. Finally, despite overall maintenance of improvement in functioning relative to baseline (pretreatment), the MTA group as a
References (49)
- et al.
The National Institute of Mental Health collaborative multisite Multimodal Treatment Study of Children with ADHD: I. background and rationale
J Am Acad Child Adolesc Psychiatry
(1995) - et al.
3-year follow-up of the NIMH MTA study
J Am Acad Child Adolesc Psychiatry
(2007) - et al.
Secondary evaluations of MTA 36-month outcomes: propensity score and growth mixture model analyses
J Am Acad Child Adolesc Psychiatry
(2007) - et al.
Medication treatment strategies in the MTA: relevance to clinicians and researchers
J Am Acad Child Adolesc Psychiatry
(1996) - et al.
Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration
J Am Acad Child Adolesc Psychiatry
(2001) - et al.
NIMH Diagnostic Interview Schedule for Children Version IV (NIMH DISCIV): description, differences from previous versions, and reliability of some common diagnoses
J Am Acad Child Adolesc Psychiatry
(2000) - et al.
Delinquent behavior and emerging substance use in the MTA at 36 months: prevalence, course, and treatment effects
J Am Acad Child Adolesc Psychiatry
(2007) - et al.
The services for children and adolescents parent interview (SCAPI): development and performance characteristics
J Am Acad Child Adolesc Psychiatry
(2004) - et al.
Symptomatic improvement in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment
J Am Acad Child Adolesc Psychiatry
(2004) - et al.
Age-dependent expression of attention deficit/hyperactivity symptoms
Psychiatr Clin North Am
(2004)
The adolescent outcome of hyperactive children diagnosed by research criteria: an 8-year prospective follow-up study
J Am Acad Child Adolesc Psychiatry
Attention-deficit hyperactivity disorder and problems in peer relations: predictions from childhood to adolescence
J Am Acad Child Adolesc Psychiatry
A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder
Arch Gen Psychiatry
Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder
Arch Gen Psychiatry
National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder
Pediatrics
National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment
Pediatrics
Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment Study of Children with ADHD (MTA): Part I: executive summary
J Atten Disord
Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment Study of Children with ADHD (MTA): Part 2: supporting details
J Atten Disord
NIMH collaborative Multimodal Treatment Study of Children with ADHD (MTA): design challenges and choices
Arch Gen Psychiatry
Comprehensive assessment of childhood attention-deficit hyperactivity disorder in the context of a multisite, multimodal clinical trial
J Atten Disord
Psychosocial treatment strategies in the MTA study: rationale, methods, and critical issues in design and implementation
J Abnorm Child Psychol
Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition (DSM-IV)
Reliability of the services for children and adolescents parent interview (SCAPI)
J Am Acad Child Adolesc Psychiatry
The Columbia Impairment Scale (CIS): pilot findings on a measure of global impairment for children and adolescents
Int J Methods Psychiatr Res
Cited by (881)
Effect of Pharmacological Treatment of Attention-Deficit/Hyperactivity Disorder on Criminality
2024, Journal of the American Academy of Child and Adolescent PsychiatryWHO Essential Medicines List and methylphenidate for ADHD in children and adolescents
2024, The Lancet PsychiatryEditorial: The Use of Continuous Performance Tasks in Attention-Deficit/Hyperactivity Disorder Diagnosis: A Cautionary Note
2024, Journal of the American Academy of Child and Adolescent PsychiatryPilot Trial of a Four-Session Parent Training Tele-Group for Adolescent ADHD
2024, Cognitive and Behavioral PracticeEffects of a Primary Care-Based Engagement Intervention for Improving Use of ADHD Treatments
2023, Journal of Pediatric Health Care
The NIMH Collaborative Multisite Multimodal Treatment Study of Children With Attention-Deficit/Hyperactivity Disorder (MTA) was a National Institute of Mental Health (NIMH) cooperative agreement randomized clinical trial involving six clinical sites. Collaborators from the National Institute of Mental Health: Peter Jensen, M.D. (currently at Columbia University), L. Eugene Arnold, M.D., M.Ed. (currently at Ohio State University), Benedetto Vitiello, M.D. (Child and Adolescent Treatment and Preventive Interventions Research Branch), Kimberly Hoagwood, Ph.D. (currently at Columbia); previous contributors from NIMH to the early phase: John Richters, Ph.D. (currently at National Institute of Nursing Research); Donald Vereen, M.D. (currently at National Institute on Drug Abuse). Principal investigators and coinvestigators from the clinical sites are as follows: University of California, Berkeley/San Francisco: Stephen Hinshaw, Ph.D. (Berkeley), Glen Elliott, Ph.D., M.D. (San Francisco); Duke University: C. Keith Conners, Ph.D., Karen Wells, Ph.D., John March, M.D., M.P.H., Jeffery Epstein, Ph.D.; University of California, Irvine/Los Angeles: James Swanson, Ph.D. (Irvine), Dennis Cantwell, M.D., (deceased, Los Angeles), Timothy Wigal, Ph.D. (Irvine); Long Island Jewish Medical Center/Montreal Children's Hospital: Howard Abikoff, Ph.D. (currently at New York University School of Medicine), Lily Hechtman, M.D. (McGill University); New York State Psychiatric Institute/Columbia University/Mount Sinai Medical Center: Laurence Greenhill, M.D. (Columbia), Jeffrey Newcorn, M.D. (Mount Sinai School of Medicine); University of Pittsburgh: William Pelham, Ph.D. (currently at State University of New York at Buffalo), Betsy Hoza, Ph.D. (currently at University of Vermont), Brooke Molina, Ph.D., Patricia Houck, MS. Original statistical and trial design consultant: Helena Kraemer, Ph.D. (Stanford University). Follow-up phase statistical collaborators: Robert Gibbons, Ph.D. (University of Illinois at Chicago), Sue Marcus, Ph.D. (Mt. Sinai College of Medicine), Kwan Hur, Ph.D. (University of Illinois at Chicago). Collaborator from the Office of Special Education Programs/U.S. Department of Education: Thomas Hanley, Ed.D. Collaborator from Office of Juvenile Justice and Delinquency Prevention/Department of Justice: Karen Stern, Ph.D
Disclosure: Dr. Jensen has received training and/or research funds from the Lowenstein Foundation, the Klingenstein Third Generation Foundation, the Annie E. Casey Foundation, Casey Family Programs, Novartis, Magellan, and Value Options. He participates in the speakers' bureaus of CMED, UCB Pharma, CME Outfitters, the Neuroscience Education Institute, Janssen-Ortho, and McNeil. He serves as a consultant to Best Practice, McNeil, Novartis, Janssen-Ortho, Otsuka, and Shire. Dr. Arnold has received research funding from the National Institute of Mental Health, Autism Speaks, Shire, Neuropharm, and CureMark. He has received consulting honoraria from Shire, Organon, Neuropharm, and Targacept. He has received speakers' honoraria from Shire. Dr. Swanson has received support for speaking at and travel to meetings from Janssen, UCB, and Novartis. Dr. Abikoff has received research funding from the National Institute of Mental Health and McNeil Pharmaceuticals. He has served on the ADHD advisory boards of Shire and Novartis. Dr. Greenhill is the recipient of the 2007 Elaine Schlosser Lewis Award for Greenhill L, Kollins S, Abikoff H, et al. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry. 2006; 45:1284–1293. He has received research funding from Otsuka Pharmaceuticals, Bristol-Myers Squibb, the National Institute of Mental Health, and Johnson & Johnson, and has served as the chair for Pfizer's ziprasidone pediatric studies. Dr. Hechtman has received research funding from the National Institute of Mental Health, Eli Lilly, GlaxoSmithKline, Janssen-Ortho, Purdue Pharma, and Shire; has been on the speakers' bureaus of the National Institute of Mental Health, Eli Lilly, Janssen-Ortho, Purdue Pharma, and Shire; and has been on the advisory boards of Eli Lilly, Janssen-Ortho, Purdue Pharma, and Shire. Dr. Hoza has received research funding from MediaBalance. Dr. Newcorn has received grants for research support from Eli Lilly and Ortho-McNeil-Janssen. He has been a consultant and/or advisor to Abbott, BioBehavioral Diagnostics, Eli Lilly, Novartis, Ortho-McNeil-Janssen, Psychogenics, Sanofi-Aventis, and Shire, and a speaker for Ortho-McNeil-Janssen. Dr. Wigal has received research funding from Eli Lilly, Shire, McNeil, Otsuka, the National Institute of Mental Health, the National Institute on Drug Abuse, and the National Institute of Child Health and Human Development. He has consulted to and/or served on the speakers' bureaus of Otsuka, McNeil, and Shire. Dr. Wells receives workshop training fees from the REACH Institute and from the state of New York. The other authors report no conflicts of interest.
The work reported was supported by cooperative agreement grants and contracts from the National Institute of Mental Health to the following: University of California, Berkeley: U01 MH50461, N01MH12009, and HHSN271200800005-C; Duke University: U01 MH50477, N01MH12012, and HHSN271200800009-C; University of California, Irvine: U01 MH50440, N01MH 12011, and HHSN271200800006-C; Research Foundation for Mental Hygiene (New York State Psychiatric Institute/Columbia University): U01 MH50467, N01 MH12007, and HHSN271200800007-C; Long Island-Jewish Medical Center U01 MH50453; New York University: N01MH12004 and HHSN271200800004-C; University of Pittsburgh: U01 MH50467, N01MH12010, and HHSN271200800008-C; and McGill University N01MH12008 and HHSN271200800003-C. The Office of Special Education Programs of the U.S. Department of Education, the Office of Juvenile Justice and Delinquency Prevention of the Justice Department, and the National Institute on Drug Abuse also participated in funding.
The opinions and assertions contained in this report are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of Health and Human Services, the National Institutes of Health, or the National Institute of Mental Health.
This article is the subject of an editorial by Dr. Philip L. Hazell in this issue.
Clinical trial registration information—Multimodal Treatment Study of Children With Attention Deficit and Hyperactivity Disorder. URL: http://www.clinicaltrials.gov. Unique identifier: NCT00000388.